These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 25757712)

  • 1. Subjective effects of prisoners using buprenorphine for detoxification.
    Johnstone A; Duffy T; Martin C
    Int J Prison Health; 2011; 7(4):52-65. PubMed ID: 25757712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring prison buprenorphine misuse in the United Kingdom: a qualitative study of former prisoners.
    Tompkins CN; Wright NM; Waterman MG; Sheard L
    Int J Prison Health; 2009; 5(2):71-87. PubMed ID: 25759139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance therapy and 3-year outcome of opioid-dependent prisoners: a prospective study in France (2003-06).
    Marzo JN; Rotily M; Meroueh F; Varastet M; Hunault C; Obradovic I; Zin A
    Addiction; 2009 Jul; 104(7):1233-40. PubMed ID: 19426291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone.
    Seifert J; Metzner C; Paetzold W; Borsutzky M; Passie T; Rollnik J; Wiese B; Emrich HM; Schneider U
    Pharmacopsychiatry; 2002 Sep; 35(5):159-64. PubMed ID: 12237786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accessing opioid agonist treatment in prison in England and Scotland remains problematic - the views of people with lived experience.
    Webster R; Fearns C; Harriott P; Millar L; Simpson J; Wallace J; Wheatley M
    Int J Prison Health (2024); 2024 May; 20(2):143-155. PubMed ID: 38984599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The paradox of control: An ethnographic analysis of opiate maintenance treatment in a Norwegian prison.
    Mjåland K
    Int J Drug Policy; 2015 Aug; 26(8):781-9. PubMed ID: 26025481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) prisons project: a randomised controlled trial comparing dihydrocodeine and buprenorphine for opiate detoxification.
    Sheard L; Wright NM; El-Sayeh HG; Adams CE; Li R; Tompkins CN
    Subst Abuse Treat Prev Policy; 2009 Feb; 4():1. PubMed ID: 19196468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) Prisons Project Study: protocol for a randomised controlled trial comparing methadone and buprenorphine for opiate detoxification.
    Sheard L; Wright NM; Adams CE; Bound N; Rushforth B; Hart R; Tompkins CN
    Trials; 2009 Jul; 10():53. PubMed ID: 19602218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients?
    Reed LJ; Glasper A; de Wet CJ; Bearn J; Gossop M
    J Clin Psychopharmacol; 2007 Apr; 27(2):188-92. PubMed ID: 17414244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine and naloxone interactions in methadone maintenance patients.
    Mendelson J; Jones RT; Welm S; Brown J; Batki SL
    Biol Psychiatry; 1997 Jun; 41(11):1095-101. PubMed ID: 9146820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability of buprenorphine from crushed and whole buprenorphine (subutex) tablets.
    Simojoki K; Lillsunde P; Lintzeris N; Alho H
    Eur Addict Res; 2010; 16(2):85-90. PubMed ID: 20130408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-release.
    Gordon MS; Kinlock TW; Schwartz RP; O'Grady KE; Fitzgerald TT; Vocci FJ
    Drug Alcohol Depend; 2017 Mar; 172():34-42. PubMed ID: 28107680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid Use Disorder and Incarceration - Hope for Ensuring the Continuity of Treatment.
    Binswanger IA
    N Engl J Med; 2019 Mar; 380(13):1193-1195. PubMed ID: 30811904
    [No Abstract]   [Full Text] [Related]  

  • 14. [Is the availability of buprenorphine/naloxone therapy for opioid-dependent inmates a necessity? ].
    Marco A; López-Burgos A; García-Marcos L; Gallego C; Antón JJ; Errasti A
    Rev Esp Sanid Penit; 2013 Feb; 15(3):105-13. PubMed ID: 24270319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine in the treatment of opiate dependence.
    Wesson DR; Smith DE
    J Psychoactive Drugs; 2010 Jun; 42(2):161-75. PubMed ID: 20648912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment.
    Springer SA; Chen S; Altice FL
    J Urban Health; 2010 Jul; 87(4):592-602. PubMed ID: 20177974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outpatient opiate detoxification treatment with buprenorphine. Preliminary investigation.
    Diamant K; Fischer G; Schneider C; Lenzinger E; Pezawas L; Schindler S; Eder H
    Eur Addict Res; 1998 Dec; 4(4):198-202. PubMed ID: 9852372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bupreorphine:a new pharmacotherapy for opioid addictions treatment.
    Stock C; Shum JH
    J Pain Palliat Care Pharmacother; 2004; 18(3):35-54. PubMed ID: 15364630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug and alcohol use and treatment for Australian Indigenous and non-Indigenous prisoners: demand reduction strategies.
    Dolan K; Rodas A; Bode A
    Int J Prison Health; 2015; 11(1):30-8. PubMed ID: 25751705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined buprenorphine and chlonidine for short-term opiate detoxification: patient perspectives.
    Wallen MC; Lorman WJ; Gosciniak JL
    J Addict Dis; 2006; 25(1):23-31. PubMed ID: 16597570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.